The company also said it plans to release results of a strategic assessment of the business on Dec. 8.
"We are working hard to create a focused business, and one better suited to generate long-term shareholder value," Patrick Balthrop, president and CEO, said in a statement.
Revenue for the three months ended Sept. 30 increased to $8.4 million from $7.1 million year over year. The Austin, Texas-based molecular biology tools company recorded $4.3 million of revenue from the sale of 177 Luminex systems and $2.1 million from consumables.
R&D spending also increased, to $900,000 in the third quarter from $700,000 in the year-ago period.
Net loss widened to $1.2 million for the period, or $.04 per share, from $800,000, or $.03 per share, year over year.
Luminex said it had around $36.3 million in cash and equivalents.